Pharming Group N.V. (PHAR)
NGM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Pharming Group N.V.
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 97.3M | 106.5M | 72.4M | 90.2M |
| Gross Profit | 90.2M | 85.4M | 65.8M | 75.7M |
| Operating Income | 15.8M | 2.0M | (5.3M) | (111K) |
| Net Income | 7.5M | 5.3M | (5.2M) | 1.6M |
| Diluted EPS | N/A | $0.07 | $-0.07 | N/A |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 205.6M | 245.3M | 297.2M | 376.1M |
| Gross Profit | 188.1M | 220.1M | 261.8M | 330.6M |
| Operating Income | 9.9M | (22.3M) | (3.7M) | 20.9M |
| Net Income | 13.7M | (10.5M) | (11.8M) | 2.9M |
| Diluted EPS | $0.19 | $-0.15 | $-0.18 | $0.04 |